GURUFOCUS.COM » STOCK LIST » USA » NAS » VistaGen Therapeutics Inc (NAS:VTGN) » Definitions » Retained Earnings
Switch to:

VistaGen Therapeutics Retained Earnings

: $-287.38 Mil (As of Jun. 2022)
View and export this data going back to 2011. Start your Free Trial

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. VistaGen Therapeutics's retained earnings for the quarter that ended in Jun. 2022 was $-287.38 Mil.

VistaGen Therapeutics's quarterly retained earnings declined from Dec. 2021 ($-250.92 Mil) to Mar. 2022 ($-267.60 Mil) and declined from Mar. 2022 ($-267.60 Mil) to Jun. 2022 ($-287.38 Mil).

VistaGen Therapeutics's annual retained earnings declined from Mar. 2020 ($-201.91 Mil) to Mar. 2021 ($-219.84 Mil) and declined from Mar. 2021 ($-219.84 Mil) to Mar. 2022 ($-267.60 Mil).


VistaGen Therapeutics Retained Earnings Historical Data

The historical data trend for VistaGen Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Retained Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -156.54 -181.13 -201.91 -219.84 -267.60

VistaGen Therapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Retained Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -227.59 -240.38 -250.92 -267.60 -287.38

VistaGen Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


VistaGen Therapeutics  (NAS:VTGN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


VistaGen Therapeutics Business Description

VistaGen Therapeutics logo
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
Adler Reid G. officer: CHIEF LEGAL OFFICER C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94090
Fitzpatrick Margaret M director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94080
Rotunno Mary L. director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94090
Curley Joanne director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Ginski Mark J officer: SENIOR VP, HEAD OF CMC 12119 CECILIA CT KINGSVILLE MD 21087
Cunningham Ann Michelle director 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Mcpartland Mark A. officer: VP Corporate Development C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan officer: CHIEF MEDICAL OFFICER 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B director 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Dotson Jerrold Duane officer: ACTING CFO 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Underdown Brian J. director C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Bonfiglio Gregory A. director 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Rice A. Franklin officer: CHIEF FINANCIAL OFFICER 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Cato Allen Easley 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713

VistaGen Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)